Ratings by Jones Trading (Debanjana Chatterjee)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/29/2026 | Alterity Therapeutics | ATHE | New Coverage | Buy (N/A) |
4.82 (4.98) |
3.32% | Details | |
| 6/29/2026 | Theravance Biopharma | TBPH | Downgrade | Hold (Buy) |
17.63 (16.93) |
-3.97% | Details | |
| 6/24/2026 | Absci Corp. | ABSI | Maintain | Buy (N/A) |
|
Details | ||
| 6/16/2026 | Spyre | SYRE | Maintain | Buy (N/A) |
|
Details | ||
| 5/12/2026 | Absci Corp. | ABSI | Maintain | Buy (N/A) |
|
Details | ||
| 5/12/2026 | AbCellera Biologics | ABCL | Maintain | Buy (N/A) |
|
Details | ||
| 5/4/2026 | Sagimet Biosciences Inc | SGMT | Maintain | Buy (N/A) |
|
Details | ||
| 4/30/2026 | Kalvista Pharmaceuticals Inc | KALV | Downgrade | Hold (Buy) |
19.24 (27.00) |
40.33% | Details | |
| 4/28/2026 | Sionna Therapeutics | SION | Maintain | Buy (N/A) |
|
Details | ||
| 4/15/2026 | MindWalk Holdings | HYFT | New Coverage | Buy (N/A) |
1.18 (1.46) |
23.73% | Details | |
| 4/15/2026 | Pharvaris B.V. | PHVS | Maintain | Buy (N/A) |
|
Details | ||
| 4/9/2026 | AbCellera Biologics | ABCL | New Coverage | Buy (N/A) |
3.43 (6.47) |
88.63% | Details | |
| 4/8/2026 | Armata Pharmaceuticals | ARMP | Maintain | Buy (N/A) |
|
Details | ||
| 3/9/2026 | Contineum Therapeutics | CTNM | Maintain | Buy (N/A) |
|
Details | ||
| 3/4/2026 | Intellia Therapeutics | NTLA | Upgrade | Buy (Hold) |
13.60 (11.38) |
-16.32% | Details | |
| 3/2/2026 | Opus Genetics | IRD | Maintain | Buy (N/A) |
|
Details | ||
| 1/5/2026 | Armata Pharmaceuticals | ARMP | New Coverage | Buy (N/A) |
6.56 (4.51) |
-31.25% | Details | |
| 12/1/2025 | Spyre | SYRE | Upgrade | Buy (Hold) |
29.75 (100.23) |
236.91% | Details | |
| 11/28/2025 | Absci Corp. | ABSI | Maintain | Buy (N/A) |
|
Details | ||
| 11/21/2025 | Contineum Therapeutics | CTNM | Maintain | Buy (N/A) |
|
Details | ||
| 11/18/2025 | Theravance Biopharma | TBPH | Maintain | Buy (N/A) |
|
Details | ||
| 11/11/2025 | Intellia Therapeutics | NTLA | Downgrade | Hold (Buy) |
9.73 (13.60) |
39.77% | Details | |
| 9/8/2025 | Sionna Therapeutics | SION | New Coverage | Buy (N/A) |
24.00 (49.41) |
105.88% | Details | |
| 8/18/2025 | Opus Genetics | IRD | Maintain | Buy (N/A) |
|
Details | ||
| 8/18/2025 | Tvardi Therapeutics Inc | TVRD | Maintain | Buy (N/A) |
|
Details | ||
| 8/18/2025 | Sagimet Biosciences Inc | SGMT | Maintain | Buy (N/A) |
|
Details | ||
| 8/15/2025 | Theravance Biopharma | TBPH | Maintain | Buy (N/A) |
|
Details | ||
| 7/17/2025 | Kalvista Pharmaceuticals Inc | KALV | Maintain | Buy (N/A) |
|
Details | ||
| 7/17/2025 | Clearside Biomedical | CLSD | Downgrade | Hold (Buy) |
0.84 (0.41) |
-51.19% | Details | |
| 6/16/2025 | Theravance Biopharma | TBPH | New Coverage | Buy (N/A) |
10.69 (17.63) |
64.92% | Details | |
| 4/28/2025 | Tvardi Therapeutics Inc | TVRD | New Coverage | Buy (N/A) |
18.85 (3.20) |
-83.02% | Details | |
| 3/13/2025 | Contineum Therapeutics | CTNM | New Coverage | (N/A) |
7.56 (14.23) |
88.23% | Details | |
| 1/27/2025 | Sagimet Biosciences Inc | SGMT | New Coverage | Buy (N/A) |
4.20 (7.82) |
86.19% | Details | |
| 12/11/2024 | Spyre | SYRE | New Coverage | Hold (N/A) |
26.81 (29.75) |
10.97% | Details | |
| 12/4/2024 | Absci Corp. | ABSI | New Coverage | Buy (N/A) |
3.15 (8.30) |
163.49% | Details | |
| 9/27/2024 | Kalvista Pharmaceuticals Inc | KALV | New Coverage | Buy (N/A) |
10.00 (19.24) |
92.4% | Details | |
| 9/19/2024 | Pharvaris B.V. | PHVS | New Coverage | Buy (N/A) |
20.26 (34.94) |
72.46% | Details | |
| 9/17/2024 | Intellia Therapeutics | NTLA | New Coverage | Buy (N/A) |
21.51 (11.38) |
-47.09% | Details | |
| 8/27/2024 | Clearside Biomedical | CLSD | Maintain | Buy (N/A) |
|
Details | ||
| 8/7/2024 | Clearside Biomedical | CLSD | New Coverage | Buy (N/A) |
1.09 (0.84) |
-22.94% | Details | |
| 8/7/2024 | EyePoint Pharmaceuticals, Inc. | EYPT | New Coverage | Buy (N/A) |
8.60 (13.30) |
54.65% | Details |
